

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD248 endosialin (TEM1)	<p>Mouse studies suggest a DNA plasmid encoding a TEM1-tetanus toxoid (TT) fusion peptide could be used as a cancer vaccine. TEM1 is overexpressed in the vasculature and stroma of many human tumors. In multiple mouse xenograft models of human cancer, vaccination with a DNA plasmid encoding Tem1-TT resulted in decreased tumor angiogenesis and growth compared with vaccination using a DNA plasmid encoding Tem1 or TT alone. Next steps include optimizing the vaccine's potency and designing a Phase I trial to evaluate it.</p> <p>SciBX 7(16); doi:10.1038/scibx.2014.454 Published online April 24, 2014</p>	<p>Patented in the U.S.; patent application filed in the EU; available for licensing</p>	<p>Facciponte, J.G. <i>et al. J. Clin. Invest.</i>; published online March 18, 2014; doi:10.1172/JCI67382 Contact: Andrea Facciabene, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa. e-mail: facciabe@mail.med.upenn.edu</p>